BISMUTH SUBSALICYLATE (bis'muth) Pepto-Bismol Classifications: gastrointestinal agent; antidiarrheal; salicylate Pregnancy Category: C |
262 mg tablets/caplets; 130 mg/15 mL, 262 mg/15 mL, 524 mg/15 mL liquid
Hydrolyzed in GI tract to salicylate, which is believed to inhibit synthesis of prostaglandins responsible for GI hypermotility and inflammation.
Effectiveness as an antidiarrheal also appears to be due to direct antimicrobial action and to an antisecretory effect on intestinal secretions exposed to toxins particularly of Escherichia coli and Vibrio cholerae.
Prophylaxis and treatment of traveler's diarrhea (turista) and for temporary relief of indigestion.
Helicobacter pylori associated with peptic ulcer disease.
Hypersensitivity to aspirin or other salicylates; concurrent use with aspirin; use for more than 2 d in presence of high fever or in children <3 y unless prescribed by physician; chicken pox or flu.
Diabetes and gout; concurrent use with salicylates and anticoagulants; pregnancy (category C), lactation.
Diarrhea Adult: PO 30 mL or 2 tab q3060min prn (max: 8 doses/d) Child: PO 36 y, 5 mL or ½ tab q3060min prn (max: 8 doses/d); 69 y, 2/3 tab or 10 mL q3060 min prn (max: 8 doses/d); 912 y, 15 mL or 1 tab q3060min prn (max: 8 doses/d) Traveler's Diarrhea Adult: PO 24 tab or 1530 mL q.i.d. for 3 wk Peptic Ulcer Disease Adult: PO 2 tablets q.i.d. with 2 additional antibiotics for 1014 d Child: PO <10 y, 15 mL q.i.d. times 6 wk |
Because bismuth subsalicylate is radiopaque, it may interfere with radiographic studies of GI tract.
Assessment & Drug Effects
Patient & Family Education